Inactive Instrument

Amyris, Inc. Share Price

AMRS

US03236M2008

Analysts' recommendations: Amyris, Inc.

18/05/23	Jefferies Downgrades Amyris to Hold From Buy, Adjusts Price Target to $0.65 From $3.10	MT
28/04/23	Canaccord Genuity Initiates Amyris at Buy With $1.50 Price Target	MT
26/04/23	Piper Sandler Adjusts Amyris' Price Target to $1 From $1.50, Keeps Neutral Rating	MT
10/11/22	JPMorgan Downgrades Amyris to Underweight From Neutral	MT
09/11/22	Oppenheimer Downgrades Amyris to Perform From Outperform, Removes $22 Price Target	MT

More recommendations

News in other languages: Amyris, Inc.

11/10/23	Ausblick Givaudan: 9-Mte-Umsatz von 5,31 Milliarden Franken erwartet
20/07/23	Après le 1er semestre, Givaudan se diversifie et augmente ses prix
20/07/23	Givaudan: fatturato in calo
12/04/23	Prévisions Givaudan: chiffre d'affaires de 1,79 milliard de francs
12/04/23	Ausblick Givaudan: Q1-Umsatz von 1,79 Milliarden Franken erwartet

More news

Managers and Directors: Amyris, Inc.

Manager	Title	Age	Since
Kathy Fortmann CEO	Chief Executive Officer	59	06/05/2024
Claudia Nohara DFI	Director of Finance/CFO	-	28/02/2025
Sunil Chandran CTO	Chief Tech/Sci/R&D Officer	-	31/12/2005

Director	Title	Age	Since
L. Doerr BRD	Director/Board Member	74	30/04/2006
Ryan Panchadsaram BRD	Director/Board Member	41	09/08/2021
J. White BRD	Director/Board Member	58	28/08/2023

More insiders

Amyris, Inc. is a synthetic biotechnology company. The component of the Company is derived from marketing and selling Clean Beauty, Personal Care, and Health & Wellness consumer products through its direct-to-consumer e-commerce platforms and a growing network of retail partners. The Companyâ€™s sustainable ingredients are sold in bulk to industrial leaders who serve Flavor & Fragrance (F&F), Nutrition, Food & Beverage, and Clean Beauty & Personal Care end markets. The ingredients and consumer products it produces by its Lab-to-Market technology platform. The Company leverages machine learning, robotics, and artificial intelligence, which enables its technology platform to rapidly bring new market at commercial scale. The Lab-to-Market technology platform utilizes optimized and automated molecular biology, analytical, and process development tools combined with machine learning algorithms and statistical models to transform the way microbes metabolize sugars.

Employees

1,598

Sector

Specialty Chemicals

More about the company

Stock Market
Stocks
AMRS Stock

The best tools reserved for subscribers to boost the performance of your investments!

02/09/25	Amyris, Inc. Appoints Dr. Sunil Chandran as Chief Technology Officer	CI
28/05/25	Amyris, Inc. acquired remaining 31% stake in Industrial Precision Fermentation Plant in Barra Bonita, Brazil from Ingredion Incorporated.	CI
03/10/24	Amyris Wins Agreement from BioMaP-Consortium to Develop Critical Medicines to Support Resilient Domestic Supply Goals	CI
07/05/24	Han Kieftenbeld to leave as Chief Financial Officer of Amyris, Inc	CI
07/05/24	Kathy L. Fortmann to Join Amyris, Inc. as Member of the Board of Directors	CI
07/05/24	Amyris, Inc. Announces Chief Executive Officer Changes	CI
07/05/24	Amyris, Inc. Emerged from Bankruptcy	CI
07/02/24	Third Amended Joint Reorganization Plan Approved for Amyris, Inc.	CI
22/01/24	Third Amended Joint Reorganization Plan Filed by Amyris, Inc.	CI
17/01/24	Notice for Auction Cancellation Filed by Amyris, Inc.	CI
10/01/24	US corporate bankruptcies hit 13-year peak in 2023	RE
05/01/24	Foris Ventures Provides Information to the Shareholders	CI
05/01/24	Advance Auto Parts Names Elizabeth Dreyer as Chief Accounting Officer	MT

04/01/24	Dr. Reddy's announces the acquisition of MenoLabs, a leading Women's health and dietary supplements portfolio of brands	AQ
22/11/23	Ninth Circuit Provides Guidance On SEC Rule 16b-3 Short-Swing Profit Liability Exemption	AQ
01/09/23	Amyris : Management Change - Form 8-K	PU
14/08/23	Amyris : Aviso aos Acionistas	PU
10/08/23	AMYRIS ANNOUNCES OPERATIONAL AND FINANCIAL RESTRUCTURING TO ADVANCE STRATEGIC TRANSFORMATION	PR

Date	Insider	Type	Main position	Quantity	% Market Cap.
07/05/24	Foris Ventures LLC	Issuer sale	Company	99,314,394	26.8864%
07/05/24	Steven Mills	Others	Director	37,404	0.0101%
07/05/24	Lisa Qi	Others	Director	37,471	0.0101%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AMYRIS, INC.	-.--%	+100.00%	-	-	745K
ECOLAB INC.	-0.48%	+1.08%	+4.13%	+85.00%	81.65B
GIVAUDAN SA	-0.74%	-1.39%	+14.47%	+30.76%	43.93B
SIKA AG	+0.80%	-4.87%	+11.42%	-17.49%	33.93B
HENKEL AG & CO. KGAA	+0.03%	-0.56%	+9.33%	+14.45%	33.24B
NOVONESIS A/S	-1.29%	-0.99%	+17.92%	+47.75%	32.58B
FUJIFILM HOLDINGS CORPORATION	-0.32%	+1.47%	-3.83%	+27.11%	26.14B
EMS-CHEMIE HOLDING AG	-0.15%	-5.42%	+50.85%	+38.74%	24B
DUPONT DE NEMOURS, INC.	+0.14%	+3.54%	-43.61%	-36.40%	18.59B
SOCIEDAD QUÍMICA Y MINERA DE CHILE S.A.	-1.25%	+0.42%	+35.93%	+18.03%	17.22B
Average	-0.32%	-0.19%	+10.73%	+23.11%	34.59B
Weighted average by Cap.	-0.38%	-0.16%	+10.22%	+35.36%

Amyris, Inc. Share Price

Stocks

AMRS

US03236M2008

Specialty Chemicals

Latest news: Amyris, Inc.

Analysts' recommendations: Amyris, Inc.

Press Releases: Amyris, Inc.

News in other languages: Amyris, Inc.

Managers and Directors: Amyris, Inc.

Latest insider transactions

Other Specialty Chemicals

Company Profile